
|Articles|October 8, 2014
- NSCLC (Issue 4)
- Volume 4
- Issue 1
The Implementation of Personalized Medicine for Lung Cancer Patients
Author(s)Vassiliki Papadimitrakopoulou, MD
Vassiliki Papadimitrakopoulou, MD, from the University of Texas MD Anderson Cancer Center, discusses the implementation of personalized medicine for lung cancer patients.
Advertisement
Vassiliki Papadimitrakopoulou, MD, Professor, Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, discusses the implementation of personalized medicine for lung cancer patients.
Articles in this issue
almost 12 years ago
The Benefit of Treating Lung Cancer with Immunotherapyalmost 12 years ago
The Cancer Genome Atlas Plays Role in Future Therapies for NSCLCalmost 12 years ago
In Practice: Systemic Treatment for Metastatic NSCLCalmost 12 years ago
The Importance of Biomarkers for Lung Canceralmost 12 years ago
Clinical Trial Profile: The OAK Studyalmost 12 years ago
Managing Side Effects of Targeted Therapies for NSCLC May Improve Outcomesalmost 12 years ago
Optimizing of Therapeutic Sequencing Being Studied in NSCLCAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Long-Term OMNIVORE Data Show Durable Treatment-Free Survival in RCC
2
Phase 3 ENHANCE Trial: Magrolimab Adds Toxicity, Not Benefit, in MDS
3
On-Body Injector Technology Streamlines Subcutaneous Myeloma Therapy
4
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
5






























